Please login to the form below

CD3

This page shows the latest CD3 news and features for those working in and with pharma, biotech and healthcare.

Affimed rockets on $5bn-plus Roche immuno-oncology deal

ALL). A third drug from the platform –CD33/CD3 T cell engager AMV564 – has been licensed to US biotech Amphivena and is in phase I for the treatment of acute myeloid

Latest news

Daily Brief: Azar blasts pharma, NICE forces MS drug prices down, Xenicos gets $30m funding

T-Guard consists of a unique combination of toxin-conjugated monoclonal antibodies that target the CD3 and CD7 molecules on T cells and NK cells.
Amgen pledges $1.5bn for CytomX preclinical cancer drugs

bispecific) antibody targeting the epidermal growth factor receptor (EGFR) and CD3 receptor that has come out of CytomX’s Probody platform. ... CytomX will handle the early stages of clinical development of the EGFR/CD3 Probody, with Amgen getting
Celgene bolsters blood cancer portfolio with $600m EngMab buy

At last year's American Society of Hematology (ASH) meeting, EngMab gave two presentations showing how antibodies binding the CD3 receptor on T cells and BCMA were able to selectively kill
Amgen leukaemia drug gets FDA priority review

Blinatumomab - which targets CD19- and CD3-expressing cells - is also in phase II trials for non-Hodgkin's lymphoma (NHL) and, according to analysts at JP Morgan, could become a ... Amgen's BiTE pipeline also includes anti-EpCAM (epithelial cell adhesion
Amgen files breakthrough leukaemia antibody in US

BiTE antibodies are designed to exert anticancer effects by directing the body's cell-destroying T lymphocytes to attack tumour cells, and in the case of blinatumomab targets CD19- and

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Taking a lean and careful approach

Its fully human engineered CD3 antibody Foralumab has reached phase II with potential for a wide range of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis,
Deal Watch June 2016

Both antibodies have a cytotoxic T-cell binding domain (CD3), which activates T-cells at the site of the tumour for killing of malignant cells, and a specific tumour antigen binding
Pharma deals during December 2014

platform. The antibody targets both CD19 and CD3 and is being developed for the treatment of B-cell malignancies.
Deal Watch table for August 2014

187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
Pharma deals during February 2014

CD123 and CD3.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences

Shailubhai takes the helm as Tiziana focuses on developing an orally administered, anti-CD3 mAb (foalumab) drug candidate to manage non-alcoholic steatohepatitis (NASH) - a liver disease that has no treatment